These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 18645351)
1. Mechanical circulatory device thrombosis: a new paradigm linking hypercoagulation and hypofibrinolysis. Nielsen VG; Kirklin JK; Holman WL; Steenwyk BL; George JF; Zhou F; Parks DA; Ellis TC ASAIO J; 2008; 54(4):351-8. PubMed ID: 18645351 [TBL] [Abstract][Full Text] [Related]
2. Contact activation prolongs clot lysis time in human plasma: role of thrombin-activatable fibrinolysis inhibitor and Factor XIII. Nielsen VG; Steenwyk BL; Gurley WQ J Heart Lung Transplant; 2006 Oct; 25(10):1247-52. PubMed ID: 17045938 [TBL] [Abstract][Full Text] [Related]
3. Hemodilution modulates the time of onset and rate of fibrinolysis in human and rabbit plasma. Nielsen VG J Heart Lung Transplant; 2006 Nov; 25(11):1344-52. PubMed ID: 17097499 [TBL] [Abstract][Full Text] [Related]
4. Clot life span model analysis of clot growth and fibrinolysis in normal subjects: role of thrombin activatable fibrinolysis inhibitor. Nielsen VG Blood Coagul Fibrinolysis; 2008 Jun; 19(4):283-7. PubMed ID: 18469549 [TBL] [Abstract][Full Text] [Related]
5. Clot lifespan model analysis of the effects of warfarin on thrombus growth and fibrinolysis: role of contact protein and tissue factor initiation. Nielsen VG; Kirklin JK; Holman WL; Steenwyk BL ASAIO J; 2009; 55(1):33-40. PubMed ID: 19092656 [TBL] [Abstract][Full Text] [Related]
6. Activation of endothelial and coagulation systems in left ventricular assist device recipients. John R; Panch S; Hrabe J; Wei P; Solovey A; Joyce L; Hebbel R Ann Thorac Surg; 2009 Oct; 88(4):1171-9. PubMed ID: 19766802 [TBL] [Abstract][Full Text] [Related]
7. Inactivation of plasminogen activator inhibitor type 1 by activated factor XII plays a role in the enhancement of fibrinolysis by contact factors in-vitro. Tanaka A; Suzuki Y; Sugihara K; Kanayama N; Urano T Life Sci; 2009 Jul; 85(5-6):220-5. PubMed ID: 19500599 [TBL] [Abstract][Full Text] [Related]
8. Patient with hypofibrinolysis-mediated thromboembolism converted to a hypercoagulable/hyperfibrinolytic state via ventricular assist device placement. Nielsen VG; Kirklin JK; Holman WL; George JF; Ellis TC; Steenwyk BL J Heart Lung Transplant; 2008 Oct; 27(10):1169-71. PubMed ID: 18926412 [TBL] [Abstract][Full Text] [Related]
10. Thrombophilia and hypofibrinolysis: pathophysiologies of osteonecrosis. Glueck CJ; Freiberg R; Tracy T; Stroop D; Wang P Clin Orthop Relat Res; 1997 Jan; (334):43-56. PubMed ID: 9005895 [TBL] [Abstract][Full Text] [Related]
11. Fibrinolysis and the risk of venous and arterial thrombosis. Meltzer ME; Doggen CJ; de Groot PG; Rosendaal FR; Lisman T Curr Opin Hematol; 2007 May; 14(3):242-8. PubMed ID: 17414214 [TBL] [Abstract][Full Text] [Related]
12. Left Ventricular Assist Device-Associated Carbon Monoxide and Iron-Enhanced Hypercoagulation: Impact of Concurrent Disease. Nielsen VG; Sobieski MA; Slaughter MS ASAIO J; 2015; 61(4):417-23. PubMed ID: 25710774 [TBL] [Abstract][Full Text] [Related]
16. Increased carbon monoxide production by hemeoxygenase-1 caused by device-mediated hemolysis: thrombotic phantom menace? Nielsen VG; Pearson EC; Smith MC Artif Organs; 2013 Nov; 37(11):1008-14. PubMed ID: 23865494 [TBL] [Abstract][Full Text] [Related]
17. Detection of carboxyhemefibrinogen and methemefibrinogen in a patient with thrombosis of a HeartMate II ventricular assist device. Smith MC; Nielsen VG ASAIO J; 2013; 59(1):93-5. PubMed ID: 23263339 [TBL] [Abstract][Full Text] [Related]
18. Low thromboembolic risk for patients with the Heartmate II left ventricular assist device. John R; Kamdar F; Liao K; Colvin-Adams M; Miller L; Joyce L; Boyle A J Thorac Cardiovasc Surg; 2008 Nov; 136(5):1318-23. PubMed ID: 19026822 [TBL] [Abstract][Full Text] [Related]
19. Kallikrein-kinin system and fibrinolysis in hereditary angioedema due to factor XII gene mutation Thr309Lys. Bork K; Kleist R; Hardt J; Witzke G Blood Coagul Fibrinolysis; 2009 Jul; 20(5):325-32. PubMed ID: 19474702 [TBL] [Abstract][Full Text] [Related]
20. Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy. John R; Kamdar F; Liao K; Colvin-Adams M; Boyle A; Joyce L Ann Thorac Surg; 2008 Oct; 86(4):1227-34; discussion 1234-5. PubMed ID: 18805167 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]